220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

Recommendations

Info

2366. Practical Statistics for Medical ResearchAltman DGISBN 0-412-27630-5 (Chapman and Hall 1991; reprint only: 1999,but 2 nd edition anticipated 2007)7. How to Report Statistics in Medicine: Annotated Guidelines forAuthors, Editors, and Reviewers (Paperback)Lang TA, Secic MAmerican College of Physicians; 2nd edition (December 30,2006)Odds Ratio, Relative Risks1. Survival analysis. A Self-learning TextKleinbaum DG2 nd editionISBN 0-387-23918-9 (Springer 2005)2. Statistical Methods in Medical ResearchArmitage P, Berry G et al.4 th edition(2002)3. Medical Statistics – A common-sense ApproachCampbell MJ & Machin D3 rd editon(John Wiley & Sons 1999)4. Applied Regression Analysis and Other Multivariable MethodsKleinbaum DG, Kupper LL, Muller KE, Nizam AISBN 0-534-20910-6 (Duxbury 1998)Mantel-Haenszel Tests1. Statistical Methods for Rates and ProportionsFleiss JL (page 173)3 rd edition(John Wiley & Sons 2003)Sequential and cross-over Trials, Bayesian and FrequentistMethods1. Statistical Issues in Drug DevelopmentSenn S(John Wiley & Sons 1997; 2 nd edition anticipated 2007)
2372. The Design and Analysis of Sequential TrialsWhitehead J (revised 2 nd edition(John Wiley & Sons 1997)Epidemiology1. Epidemiology in MedicineHennekens CH, Buring JEISBN 0-316-35636-0 (Little, Brown 1987)2. Modern EpidemiologyRothman K, Greenland S, Lash TLLippincott Wilkins 20083. EpidemiologyL. GordisSaunders; 4 edition (May 14, 2008)4. Clinical Epidemiology: The EssentialsFletcher RH, Fletcher SWLippincott Williams & Wilkins; Fourth Edition edition (March 1,2005)Health Economics/Pharmacoeconomics/Decision Analysis1. Introduction to health economics for physiciansMeltzer MILancet 2001;358(9286):993–82. Decision Making in Health and MedicineHunink M, Glasziou PISBN 0-521-77029-7 (Cambridge University Press 2001)3. Methods for the Economic Evaluation of Health Care ProgrammesDrummond M et al.Oxford, 3 rd Edition 20054. Designing and Conducting Cost-Effectiveness Analyses in Medicineand Health CareMuennig P, Khan KJossey-Bass; 1 st edition (March 18, 2002)5. Cost-effectiveness in Health and MedicineSiegel JE, Russell LB, Weinstein MC, Gold MRISBN 0-19-510824-8 (Oxford University Press 1996)
Page 3 and 4:
Gerhard NahlerDictionary ofPharmace
Page 5 and 6:
ForewordIn the beginning was the wo
Page 7 and 8:
Foreword of the 1st editionThe evol
Page 9 and 10:
IXPreface of the 1st editionFinally
Page 11 and 12:
1abbreviated new drug application A
Page 13 and 14:
3actual-treated analysis syn. as-tr
Page 15 and 16:
5of a sign or symptom which is easi
Page 17 and 18:
7allele frequency Often called gene
Page 19:
9anecdotal study → see observatio
Page 22 and 23:
12audaudit trail → see data trail
Page 24 and 25:
14bento calculate the posterior odd
Page 26 and 27:
16biolent; FDA: “bioequivalent dr
Page 28 and 29:
18bloblock size Size of consecutive
Page 30 and 31:
20caccachexia def. unintended and p
Page 32 and 33:
22cascer patients); the method for
Page 34 and 35:
24cemCE marking (of a medical devic
Page 36 and 37:
26chrtain DNA and proteins; genes a
Page 38 and 39:
28cleclerical error syn. key-punch
Page 40 and 41:
30clijournals: Writing and editing
Page 42 and 43:
32coithis treatment (e.g. to follow
Page 44 and 45:
34comreporting”; → see also see
Page 46 and 47:
36connal data. It should be possibl
Page 48 and 49:
38conof exposure-outcome associatio
Page 50 and 51:
40coopolymer matrix), wax matrices,
Page 52 and 53:
42cosare increasingly used to facil
Page 54 and 55:
44cumcumulative incidence Number of
Page 56 and 57:
46datdata dredging Multiple, exhaus
Page 58 and 59:
48datto confirm that the correct pr
Page 60 and 61:
50devcomparison, e.g. two group par
Page 62 and 63:
52diadiagnostic A product used for
Page 64 and 65:
54disdisqualification rate → see
Page 66 and 67:
56drudrug FDA: (1) substance recogn
Page 68 and 69:
58druTable 1Determining the Probabi
Page 70 and 71:
60ecbEC birth date First date on wh
Page 72 and 73:
62effensures and declares that the
Page 74 and 75:
64eleelectronic signature OECD: “
Page 76 and 77:
66enzinformation about the physical
Page 78 and 79:
68ethofficial action indicated; OAI
Page 80 and 81:
70excglidants (improving powder flo
Page 82 and 83:
72expin tabular or in graphic form
Page 84 and 85:
74facfactorial design D. where it i
Page 86 and 87:
76foomised, IIa walking distance >
Page 88 and 89:
78gamgamma error syn. type III erro
Page 90 and 91:
80gengeneric name syn. internationa
Page 92 and 93:
82googood clinical research practic
Page 94 and 95:
84halhalf life (t 1/2) Time within
Page 96 and 97:
86heaprofiles are designed for a wi
Page 98 and 99:
88icdICD-9 code International Class
Page 100 and 101:
90impthey choose to submit manuscri
Page 102 and 103:
92infbe given to the person signing
Page 104 and 105:
94insincluding at least one member
Page 106 and 107:
96intinternal audit → see audit.i
Page 108 and 109:
98invinvestigational drug syn. inve
Page 110 and 111:
100isoquality intentions concerning
Page 112 and 113:
102kapKaplan-Meier method syn. prod
Page 114 and 115:
104lablabelling FDA: “all labels
Page 116 and 117:
106lifprotection; since costs of la
Page 118 and 119:
108identified amount produced in a
Page 120 and 121:
110masmaster file → see Drug Mast
Page 122 and 123:
112medto the FDA by phone as soon a
Page 124 and 125:
114micby chemicals; → see also an
Page 126 and 127:
116monmonitor’s visit log list sy
Page 128 and 129:
11890 days), certifies the dossier
Page 130 and 131:
120natnational drug list syn. natio
Page 132 and 133:
122nofno-fault insurance syn.: no-f
Page 134 and 135:
124null-hypothesis (Ho) Statistical
Page 136 and 137:
126oncgests carcinogenic potential,
Page 138 and 139:
128outintroduced in Japan (limit: J
Page 140 and 141:
130pacpackage insert → see patien
Page 142 and 143:
132patpatient log list → see subj
Page 144 and 145:
134perthe market authorisation stat
Page 146 and 147:
136phaing price (USA 42%, Western a
Page 148 and 149:
138phatics and observational, non-e
Page 150 and 151:
140pheunder non-trial conditions; t
Page 152 and 153:
142pooing conventional procedures o
Page 154 and 155:
144powoccurs; → see also Individu
Page 156 and 157:
146preassessments are harmonised (e
Page 158 and 159:
148proproduct licence application (
Page 160 and 161:
150rejected and not the confidence
Page 162 and 163:
152quatice; it operates upon all me
Page 164 and 165:
154racracemate equimolar mixture of
Page 166 and 167:
156rarall member states; after the
Page 168 and 169:
158refreference pricing syn. fixed
Page 170 and 171:
160reprepeated measures design D. w
Page 172 and 173:
162ressize of one or more measurabl
Page 174 and 175:
164rougastric emtying; dermal: lipi
Page 176 and 177:
166safsafety alert Voluntary commun
Page 178 and 179:
168serof true positive plus false n
Page 180 and 181:
170sinsingle-dose toxicity syn. acu
Page 182 and 183:
172sporive from a study or any orga
Page 184 and 185:
174staical trials; SOP should descr
Page 186 and 187:
176strstrength of medication; amoun
Page 188 and 189:
178subsubject identification code l
Page 190 and 191:
180methods of s.a. are the actuaria
Page 192 and 193:
182three-way crossover design → s
Page 194 and 195:
184toxthe FDA still requests 12 mon
Page 196 and 197: 186treon how long the desired effec
Page 198 and 199: 188vacvaccine A preparation that co
Page 200 and 201: 190as ideal drug and is distributed
Page 202 and 203: 192welestablished in previous ratin
Page 204 and 205: 194whowhich can be used because dru
Page 206 and 207: 196xenotransplantation Animal-to-hu
Page 208 and 209: 198zero order kinetics → see kine
Page 210 and 211: 200ADRADRACADROITADRRSADsAdSADTAEAE
Page 212 and 213: 202ASCOASIASMFASRAS-ODNATCATCCAUCAV
Page 214 and 215: 204CADD Computer Assisted Drug Desi
Page 216 and 217: 206ChBCHDCHFCHMPCHOCHOPCICIBCIMCIOM
Page 218 and 219: 208CRUCSCSACSDCSMCSRCSPCTCTACTCCTDC
Page 220 and 221: 210DOBDoHD.P.DPMDRFDRLDSDDSMDSMBDSR
Page 222 and 223: 212EPDEPhMRAEPLCePROEPSERERCPESCOPE
Page 224 and 225: 214GHTFGIGILSPGITGLCGMGMCGM-CSFGMMG
Page 226 and 227: 216ICD-9ICD-10ICDAICD-OICEICGEBICHI
Page 228 and 229: 218LMWHLOCFLPILPOLRECLRTILUTILUTSLV
Page 230 and 231: 220NANACDSNADNADANAFNAFTANAINAPMNAS
Page 232 and 233: 222PCAPatient Controlled AnalgesiaP
Page 234 and 235: 224RCGPRCCRCTR&DRDARDERDSREMRFPRHAR
Page 236 and 237: 226StpSURSUSARSuspSVTTAATAPTBTBITCI
Page 238 and 239: 228Selected bibliographyEuropean Co
Page 240 and 241: 230WHOAdverse reaction dictionary.
Page 242 and 243: 232Drug Research & Development1. Ph
Page 244 and 245: 2344. The Practice of Medicinal Che
Page 248 and 249: 2386. Medical Decision MakingSox H.
Page 250 and 251: 240IFAPPInternational Federation of
Page 252 and 253: 242http://www.infobiogen.fr/service
Page 254: 244http://medicine.iupui.edu/flockh
show all

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

Create successful ePaper yourself

Delete template?

Save as template?